Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 16 of 16 publications.

Li D, Tan A, Hernandez S, Reilly N, Bussberg C, Mansfield C. Predicting treatment choices for unresectable hepatocellular carcinoma (HCC): results from a patient preference study. Poster presented at the AASLD 2022 The Liver Meeting; November 4, 2022. Washington, DC. [abstract] Hepatology. 2022 Oct 21; 76(S1):S1312. doi: 10.1002/hep.32697

Doward L, Twiss J, Breckons M, Balp MM, Pettersson B, McSweeney L, Oluboyede Y, Vale L, Brass C, Anstee QM, Sanyal AJ. Evaluation of the NASH-CHECK patient-reported outcome instrument for patients with nonalcoholic steatohepatitis (NASH) with compensated cirrhosis. Poster presented at the AASLD Liver Meeting; November 12, 2021. Anaheim, CA. [abstract] Hepatology. 2021 Oct 1; 74(S1):1007A. doi: 10.1002/hep.32188

Whalley D, Twiss J, Doward L, Balp MM, Brass C, Tietz A, Loeffler J, Lopez P, Lawitz EJ, Sanyal AJ. A novel patient-reported outcome measure indicates low burden of treatment among patients with non-alcoholic steatohepatitis: interim results from a phase 2 trial of tropifexor. Poster presented at the AASLD 2020 annual meeting; November 13, 2020. Boston, MA. [abstract] Hepatology. 2020 Oct 1; 72(S1):1005A. doi: 10.1002/hep.31579

Doward L, Twiss J, Whalley D, Balp MM, Brass C, Loeffler J, Cryer DR, Cai J, Lopez P, Lawitz EJ, Anstee QM, Sanyal AJ. Development of NASH-CHECK: a new patient-reported outcome measure for NASH. Poster presented at the AASLD 2020 annual meeting; November 13, 2020. Boston, MA. [abstract] Hepatology. 2020 Oct 1; 72(S1):1014A-5A. doi: 10.1002/hep.31579

Schlatter F, Piquerez A, Habermacher M, Ragettli MS, Roosli M, Brink M, Cajochen C, Probst-Hensch N, Foraster M, Wunderli J-M. Validation of large scale noise exposure modelling by long-term measurements. Noise Mapp. 2017 Dec 22;4:75-86. doi: 10.1515/noise-2017-0006

Doward LC, Balp M-M, Twiss J, Slota C, Cryer D, Langford A, Collen R, Agashivala N, Brass CA, Anstee QM, Sanyal AJ. Understanding the patient-perceived impact of nonalcoholic steatohepatitis: raising the volume on a silent disease. Poster presented at the 2017 AASLD Liver Meeting; October 23, 2017. Washington, DC. [abstract] Hepatology. 2017 Jul; 66(1 Suppl):1182A.

Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson JR. Projections using decision-analytic modeling of long-term clinical value of telaprevir for the treatment of HCV patients who had failed prior peginterferon/ribavirin treatment. Poster presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Conference; November 2011. San Francisco, CA. [abstract] Hepatology. 2011 Oct 1; 54(Suppl. 1):802A-3A.

Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Di Bisceglie AM. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology. 2010 Dec 1;52(6):1906-14. doi: 10.1002/hep.23947

Pockros PJ, Hamzeh FM, Martin P, Lentz E, Zhou X, Govindarajan S, Lok AS. Histologic outcomes in hepatitis C–infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology. 2010 Oct 1;52(4):1193-200.

Suchdev PS, Ruth L, Obure A, Were V, Ochieng C, Ogange L, Owuor M, Ngure F, Quick R, Juliao P, Jung C, Teates K, Cruz K, Jefferds MED. Monitoring the marketing, distribution, and use of Sprinkles micronutrient powders in rural western Kenya. Food Nutr Bull. 2010 Jun;31(2 Suppl):S168-78. doi: 10.1177/15648265100312S209

Williams RE, Kalilani L, DiBenedetti D, Zhou X, Fehnel SE, Clark RV. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas. 2007 Nov 1;58(2007):348-58.

Sorensen HT, Lash T, Rothman KJ. Beyond randomized controlled trials. A critical comparison of trials with non-randomized studies. Hepatology. 2006 Nov;44(5):1075-82. doi: 10.1002/hep.21404

Appt SE, Clarkson TB, Lees CJ, Anthony MS. Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys. Maturitas. 2006 Sep 20;55(2):187-94.

Carroll I, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. Eur J Pharmacol. 2004 Oct 6;501(1-3):111-9.

Clarkson TB, Anthony MS, Cline JM, Lees CJ, Ederveen AG. Multisystem evaluations of the long-term effects of tibolone on postmenopausal monkeys. Maturitas. 2004 Aug 30;48(Suppl 1):24-9. doi: 10.1016/j.maturitas.2004.02.011

Johannes CB, Avis NA. Gender differences in sexual activity among mid-aged adults in Massachusetts. Maturitas. 1997 Apr;26(3):175-84.